Breaking News, Collaborations & Alliances

NEC Bio Therapeutics Taps AGC Biologics for Personalized Cancer Vaccine Production

Collaboration aims to enhance the production of personalized cancer treatments by leveraging the biotech strengths of both companies.

Author Image

By: Charlie Sternberg

Associate Editor

NEC Bio Therapeutics and AGC Biologics have joined forces to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based DNA vaccine designed to target patient-specific tumor neoantigens. This collaboration aims to enhance the production of personalized cancer treatments by leveraging the biotechnology strengths of both companies.   NEC Bio Therapeutics, a Mannheim based German company focused on clinical development of innovative drugs by using proprietary AI, is developing NEC...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters